Literature DB >> 20477235

Tuberculosis vaccines: present and future.

Angela M Minassian1, Helen McShane.   

Abstract

There has never been a greater need for a new protective tuberculosis vaccine. Bacille Calmette-Guerin remains the cornerstone of any vaccine strategy, but improving its immunogenicity and efficacy has now become an urgent global health priority. This review discusses the main vaccines currently in clinical development and other novel vaccine strategies in the pipeline. It addresses the key questions in vaccine design, including antigen selection, route of vaccine delivery and immune correlates of vaccine-induced protection. There is an opportunity to identify such correlates from ongoing and future Phase II/III trials and, as these emerge, they can be used to validate the most relevant and predictive animal models with which to develop the next generation of new vaccines.

Entities:  

Year:  2008        PMID: 20477235     DOI: 10.1586/17476348.2.6.721

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  5 in total

Review 1.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

2.  Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.

Authors:  Angela M Minassian; Edward O Ronan; Hazel Poyntz; Adrian V S Hill; Helen McShane
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

3.  A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.

Authors:  Angela M Minassian; Iman Satti; Ian D Poulton; Joel Meyer; Adrian V S Hill; Helen McShane
Journal:  J Infect Dis       Date:  2012-04-01       Impact factor: 7.759

4.  A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults.

Authors:  Angela M Minassian; Rosalind Rowland; Natalie E R Beveridge; Ian D Poulton; Iman Satti; Stephanie Harris; Hazel Poyntz; Matthew Hamill; Kristin Griffiths; Clare R Sander; David R Ambrozak; David A Price; Brenna J Hill; Joseph P Casazza; Daniel C Douek; Richard A Koup; Mario Roederer; Alan Winston; Jonathan Ross; Jackie Sherrard; Guy Rooney; Nicola Williams; Alison M Lawrie; Helen A Fletcher; Ansar A Pathan; Helen McShane
Journal:  BMJ Open       Date:  2011-11-14       Impact factor: 2.692

Review 5.  Utilizing poxviral vectored vaccines for antibody induction-progress and prospects.

Authors:  Simon J Draper; Matthew G Cottingham; Sarah C Gilbert
Journal:  Vaccine       Date:  2013-06-05       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.